Filtered By:
Cancer: Breast Cancer
Drug: Metformin

This page shows you your search results in order of date.

Order by Relevance | Date

Total 249 results found since Jan 2013.

Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer
J Clin Oncol. 2023 Sep 11:JCO2300296. doi: 10.1200/JCO.23.00296. Online ahead of print.ABSTRACTClinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Metformin has been associated with lower cancer risk in epidemiologic and preclinical research. In the MA.32 rando...
Source: Clinical Breast Cancer - September 11, 2023 Category: Cancer & Oncology Authors: Pamela J Goodwin Bingshu E Chen Karen A Gelmon Timothy J Whelan Marguerite Ennis Julie Lemieux Jennifer A Ligibel Dawn L Hershman Ingrid A Mayer Timothy J Hobday Judith M Bliss Priya Rastogi Manuela Rabaglio-Poretti Alastair M Thompson Daniel W Rea Paul M Source Type: research

The Effect of Metformin on Triple-Negative Breast Cancer Cells and Nude Mice
This study delves deeper into the impact of metformin on TNBC by examining changes in proliferation, apoptosis, invasion, migration, and adhesion of TNBC cells, specifically MDA-MB-231, post-metformin exposure. The treatment of MDA-MB-231 with metformin in immunodeficient nude mice led to discernible changes in tumor metrics such as size, weight, lymph node engagement, and angiogenesis. Post-treatment, MDA-MB-231 cells exhibited a marked decline in proliferation, invasion, migration, and adhesion, alongside a significant rise in apoptosis. In the in vivo model with nude mice, tumors displayed notable reductions in size and...
Source: Alternative Therapies in Health and Medicine - August 26, 2023 Category: Complementary Medicine Authors: Jin Song Junfeng Du Lili Han Xue Lin Cibo Fan Gang Chen Source Type: research

Efficacy of metformin in prevention of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled trial
Conclusion: The use of metformin in breast cancer patients offered a marked protection against paclitaxel-induced PN, which translated to better patient QoL. Clinical Trial Registration: https://classic.clinicaltrials.gov/ct2/show/NCT05351021, identifier NCT05351021.PMID:37583905 | PMC:PMC10424931 | DOI:10.3389/fphar.2023.1181312
Source: Cancer Control - August 16, 2023 Category: Cancer & Oncology Authors: Hala M Bakry Noha O Mansour Tawfik R ElKhodary Moetaza M Soliman Source Type: research

Metformin combined with glucose starvation synergistically suppress triple-negative breast cancer by enhanced unfolded protein response
In conclusion, our study suggests that the synergistic effects of MET and glucose deprivation suppress cell proliferation in TNBC by activating pro-apoptotic molecules through UPRER stress. These findings have potential implications for the anti-tumor application of MET in TNBC.PMID:37473529 | DOI:10.1016/j.bbrc.2023.07.029
Source: Cell Research - July 20, 2023 Category: Cytology Authors: Ying Li Qingqian Zhang Jintao Yang Weiping He Yulan Jiang Yu Chen Yifan Wang Source Type: research

Inhibition of multiple uptake transporters in cardiomyocytes/mitochondria alleviates doxorubicin-induced cardiotoxicity
In conclusion, our study clarified the role of multiple transporters, especially OCTN2, in DOX uptake in cardiomyocytes/mitochondria; metformin alleviated DOX-induced cardiotoxicity without compromising its antitumor efficacy by selective inhibition of multiple transporters mediated DOX accumulation in myocardium/mitochondria.PMID:37453608 | DOI:10.1016/j.cbi.2023.110627
Source: Chemico-Biological Interactions - July 15, 2023 Category: Molecular Biology Authors: Yaodong Yi Hengbin Zhang Mingyang Chen Binxin Chen Yingchun Chen Ping Li Hui Zhou Zhiyuan Ma Huidi Jiang Source Type: research

Metformin ameliorates BMP2 induced adipocyte-like property in breast cancer cells
This study reports that breast cancer cells exhibit inherent adipocyte-like property which is further enhanced in presence of BMP2. Antidiabetic metformin inhibits BMP2 induced adipocyte-like potential in breast cancer cells. Interestingly, breast cancer cells not only show lipid accumulation but also have ability to release lipid content. Thus, this study centers around the presence of the adipocyte cell-like property in breast cancer cells, the significance of BMP2 and metformin that may be explored in designing therapeutics against breast cancer.PMID:37406485 | DOI:10.1016/j.bbrc.2023.06.044
Source: Biochemical and Biophysical Research communications - July 5, 2023 Category: Biochemistry Authors: Sneha Soni Pooja Yadav Chandi C Mandal Source Type: research

The efficacy of metformin as adjuvant to chemotherapy on IGF levels in non-diabetic female patients with progressive and non-progressive metastatic breast cancer
CONCLUSIONS: Metformin as an adjuvant to chemotherapy in MBC patients had no significant effect on reducing IGF-l levels which promotes the inhibition of the proliferation of BC cells in MBC patients.PMID:37318494 | DOI:10.26355/eurrev_202306_32638
Source: Pharmacological Reviews - June 15, 2023 Category: Drugs & Pharmacology Authors: N M Essa M O Elgendy A Gabr M M Mahmoud A A Alharbi H M Tashkandi H F Salem S Harakeh M S Boshra Source Type: research